Results 121 to 130 of about 40,250 (264)

Clinical Outcomes with the Use of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Among Patients with Diabetes Mellitus and COVID-19: A Systematic Review of Observational Studies. [PDF]

J Clin Med
Alkhalifah SA, Alshahrani WA, Alshehri AM, Al Yami MS.   +3 more
europepmc   +1 more source

Impact of mono‐ or multitherapy on ocular surface health and quality of life after 5 years of follow‐up in the Glaucoma Intensive Treatment Study (GITS)

Acta Ophthalmologica, EarlyView.
Abstract Aim To evaluate the impact of initial mono‐ versus multitherapy on the ocular surface and related quality of life after 5 years follow‐up in the Glaucoma Intensive Treatment Study (GITS). Method The study included patients with primary open‐angle glaucoma and pseudoexfoliation glaucoma who completed 5‐year follow‐up in GITS.
Gauti Jóhannesson, Christina Lindén, Johan Aspberg, Sabina Andersson‐Geimer, Anders Heijl, Boel Bengtsson, Dorothea Peters   +6 more
wiley   +1 more source

External validation and application of a machine learning-based model for diabetes progression in prediabetes. [PDF]

Front Endocrinol (Lausanne)
Wang S, Huang Q, Luo Y, Luo Y, Wu H, Lian Z, Ji L, Zou X.   +7 more
europepmc   +1 more source

Secular Trend in Glycaemic Management in Type 2 Diabetes Patients With and Without Cirrhosis Between 2000 and 2023: A Territory‐Wide Cohort Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In this territory‐wide cohort study, improving glycemic control can be observed regardless of cirrhosis status. Oral antidiabetic medication was more often used in the non‐cirrhosis group, and insulin was preferred in patients with decompensated cirrhosis, who exhibited an increasing incidence of hypoglycemia over the years and need individualized ...
Mary Yue Wang, Sherlot Juan Song, Nana Peng, Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong, Jimmy Che‐To Lai, Terry Cheuk‐Fung Yip   +6 more
wiley   +1 more source

Gingival-Dominant Presentation of DPP-4 Inhibitor-Associated Bullous Pemphigoid: A Case Report. [PDF]

Cureus
Fujii Y, Kataoka T, Togashi C, Ishikawa M, Kawase-Koga Y.   +4 more
europepmc   +1 more source

Is There a Causal Link Between GLP‐1 Receptor Agonists and Non‐Arteritic Anterior Ischaemic Optic Neuropathy? A Critique of the Clinical Evidence

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are widely used for managing Type 2 diabetes and obesity, with well‐documented and significant cardiometabolic benefits. Recent observational reports and pharmacovigilance data have raised concerns about a possible association between GLP‐1RAs‐particularly semaglutide‐ and non‐arteritic ...
Helen V. Danesh‐Meyer, Joseph F. Rizzo III   +1 more
wiley   +1 more source

Impact of Lipid Source on Protein Digestion and Absorption in Skimmed Goat Milk and Associated Intestinal Oxidative Stress Responses in a Caco-2 Cell Model. [PDF]

Foods
Xue H, Ding B, He B, Ma J, Lian Y, Dong W.   +5 more
europepmc   +1 more source

Banting memorial lecture 2025: Aligning clinical practice, policy and research

Diabetic Medicine, EarlyView.
Abstract National clinical leadership, on a background of clinical practice and clinical research, provides unique perspectives. I have focused the Banting Memorial Lecture 2025 on the implementation of national programmes across England since 2013, for which, along with colleagues at NHS England, I successfully made the case for investment, led the ...
Jonathan Valabhji
wiley   +1 more source

Multitargeting Pt(IV) Anticancer Prodrugs Bearing Mono- and Bis-Probenecid Ligands in Axial Positions: Synthesis and Evaluation of Biological Activity. [PDF]

Pharmaceuticals (Basel)
Qiu P, Zhang Y, Dou Y, Cheng Z, Wu X, Zhang S, Wang F, Wu K.   +7 more
europepmc   +1 more source

Efficacy and safety of switching to iGlarLixi from premixed insulin therapy in patients with type 2 diabetes: A real‐world experience

Diabetic Medicine, EarlyView.
Abstract Aims Fixed‐ratio combinations such as iGlarLixi are recommended over premixed insulin as first‐line injectable therapy for type 2 diabetes mellitus (T2DM), yet real‐world evidence on transitions from premix to iGlarLixi remains limited. This study aimed to evaluate the efficacy and safety of switching from premixed insulin to iGlarLixi in a ...
Chun‐Jui Huang, Shun‐Jie Yang, Cheng‐Pin Cheng, Chun‐Hsing Lin, Ya‐Chun Lee, Harn‐Shen Chen   +5 more
wiley   +1 more source